StreetInsider.com News Articles

Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target

Wed, 14 Oct 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Deep Origin today announced a multi-target AI-driven drug discovery collaboration with BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The collaboration has reached its first milestone: novel small-molecule hits identified computationally by Deep Origin against a novel BioAge target have been validated in BioAge’s wet lab.

The collaboration aims to speed drug development against novel targets by utilizing hybrid AI and physics-based models for computational drug discovery. Under the agreement,

Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target

Wed, 14 Oct 2026 08:00:00 -0400

The collaboration aims to speed drug development against novel targets by utilizing hybrid AI and physics-based models for computational drug discovery. Under the agreement,

UBS Starts BioAge Labs Inc (BIOA) at Neutral

Mon, 12 Oct 2026 02:23:39 -0400

UBS analyst Alice Nettleton initiates coverage on BioAge Labs Inc (NASDAQ: BIOA) with a Neutral rating and a price target of $8.00.

The analyst comments: “We initiate coverage of BioAge Labs (BIOA) with a Neutral rating and $8 PT. While we view lead asset BGE-102 as a potentially differentiated NLRP3 inhibitor, BIOA's decision to deprioritize the atherosclerotic cardiovascular disease (ASCVD) reduces exposure to potentially its largest TAM. Although the company could revisit ASCVD development if future data from competing programs further validate the opportunity, this is not our base case. Instead, BIOA is focused on diabetic macular edema (DME), with a

UBS Starts BioAge Labs Inc (BIOA) at Neutral

Mon, 12 Oct 2026 02:23:39 -0400

UBS analyst Alice Nettleton initiates coverage on BioAge Labs Inc (NASDAQ: BIOA) with a Neutral rating and a price target of $8.00.

Form 8-K BioAge Labs, Inc. For: Oct 02

Fri, 02 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261002/27142411.html

BioAge Labs to Present at Upcoming Investor Conferences

Fri, 25 Sep 2026 16:30:00 -0400

EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

• ROTH Healthcare Opportunities Conference (New York, September 29, 2026): BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, Associate Director, Strategy & Investor Relations, will participate in one-on-one meetings.

• Stifel Virtual Cardiometabolic Forum (September 30, 2026): BJ Sullivan, PhD, Chief Strategy Officer, is scheduled

BioAge Labs to Present at Upcoming Investor Conferences

Fri, 25 Sep 2026 16:30:00 -0400

• Stifel Virtual Cardiometabolic Forum (September 30, 2026): BJ Sullivan, PhD, Chief Strategy Officer, is scheduled

First patient treated with Leqembi® (lecanemab) in Sweden

Tue, 22 Sep 2026 10:39:00 -0400

STOCKHOLM, Sept. 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi is now available at a private clinic in Sweden and that the first patient has started treatment. This is the first time a patient in Sweden has been treated outside of a clinical study since Leqembi received EU approval in April 2025.

First patient treated with Leqembi® (lecanemab) in Sweden

Tue, 22 Sep 2026 10:39:00 -0400

First patient treated with Leqembi® (lecanemab) in Sweden

Tue, 22 Sep 2026 10:39:00 -0400

First patient treated with Leqembi® (lecanemab) in Sweden

Tue, 22 Sep 2026 10:39:00 -0400

Japan approves subcutaneous autoinjector form of Leqembi for Alzheimer's

Wed, 16 Sep 2026 02:23:01 -0400

Eisai, a partner of BioArctic AB (NASDAQ Stockholm: BIOA B), announced that Japan has approved a subcutaneous autoinjector formulation of Leqembi, known as Leqembi Pen, as a new route of administration for the treatment of early Alzheimer's disease.

The Leqembi Pen allows patients or care partners to self-administer treatment at home via two injections totaling 500 mg, given once weekly. Each injection takes approximately 15 seconds. The approval adds to the existing intravenous (IV) formulation, which requires administration every two weeks in a hospital setting.

Japan is the third country globally to approve the subcutaneous formulation of Leqembi. The approval is based

Japan approves subcutaneous autoinjector form of Leqembi for Alzheimer's

Wed, 16 Sep 2026 02:23:01 -0400

Japan is the third country globally to approve the subcutaneous formulation of Leqembi. The approval is based

Leqembi® Pen subcutaneous formulation approved in Japan

Wed, 16 Sep 2026 02:15:00 -0400

STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has been approved as a new route of administration for the treatment of early Alzheimer's disease.

Leqembi Pen enables patients or care partners to self-administer treatment, with

Leqembi® Pen subcutaneous formulation approved in Japan

Wed, 16 Sep 2026 02:15:00 -0400

Leqembi Pen enables patients or care partners to self-administer treatment, with

Leqembi® Pen subcutaneous formulation approved in Japan

Wed, 16 Sep 2026 02:15:00 -0400

Leqembi Pen enables patients or care partners to self-administer treatment, with

Leqembi® Pen subcutaneous formulation approved in Japan

Wed, 16 Sep 2026 02:15:00 -0400

Leqembi Pen enables patients or care partners to self-administer treatment, with

Leqembi Iqlik® for initiation treatment launched in the US

Mon, 24 Aug 2026 08:39:00 -0400

STOCKHOLM, Aug. 24, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi Iqlik®), which was approved by the FDA on July 13, now is available in the US for initiation therapy for early Alzheimer's disease[1]. Leqembi Iqlik is the first-of-its-kind anti-amyloid treatment that offers at-home dosing for initiation and maintenance (approved in the US).